Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs TORM plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while TORM plc trades at $29.17 (market cap $2.94B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13.6× TORM plc's market cap, and TORM plc pays a 9.5% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TRMD | |
|---|---|---|
Market Cap | $39.89B | $2.94B |
Sector | Health | Technology |
52-Week High | $491.22 | $34.87 |
52-Week Low | $278.09 | $17.46 |
Enterprise Value | $38.15B | $3.82B |
Dividend Yield | — | 9.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TRMD trades at $29.48, up 5.06% today, with technical indicators showing a neutral bias and support near $28. The stock exhibits strong profitability with a 24.41% net margin and attractive valuation at a P/E of 8.65. Recent Q1 2026 earnings missed estimates but full-year guidance was raised, reflecting robust tanker market conditions. A $0.70 dividend for H1 2026 underscores shareholder returns.
Outlook remains positive given firm freight rates and strategic execution, though volatility from geopolitical factors and earnings misses pose risks. Analyst consensus is unanimously bullish, supporting upside potential if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
